Preview

Качественная клиническая практика

Расширенный поиск

Приверженность фармакотерапии сердечно-сосудистых заболеваний: современное состояние вопроса

Полный текст:

Аннотация

В настоящей статье авторы затрагивают проблему низкой приверженности фармакотерапии у пациентов с сердечно-сосудистыми заболеваниями. В условиях реальной клинической практики низкая приверженность существенно снижает эффективность фармакотерапии, повышая риск сердечно-сосудистых осложнений и расходы на лечение. Данная проблема впервые была поднята рядом зарубежных учёных ещё в 90-х годах прошлого столетия, а официально признана Всемирной организацией здравоохранения в 2003 году. В статье приведены данные по распространённости явления низкой приверженности в популяции больных сердечно-сосудистой патологией, а также описаны основные факторы, связанные со снижением приверженности фармакотерапии. Представлен обзор широко используемых за рубежом непрямых методов оценки приверженности. С целью решения обсуждаемой проблемы в последние годы активно ведётся разработка и внедрение в практику различных мер, направленных на формирование у пациентов высокой приверженности фармакотерапии. В статье описаны результаты наиболее значимых исследований, посвящённых изучению эффективности таких мер. Показано положительное влияние на приверженность пациентов, однако только в части исследований удалось при этом продемонстрировать снижение риска неблагоприятных клинических исходов сердечно-сосудистых заболеваний, что подтверждает необходимость дальнейшего изучения проблемы повышения приверженности фармакотерапии, в том числе в условиях отечественной клинической практики.

Об авторах

С. Б. Фитилёв
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Фитилёв Сергей Борисович - д. м. н., профессор, Медицинский институт, кафедра общей и клинической фармакологии. SPIN-код: 8287-8456

Москва



А. В. Возжаев
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Возжаев Александр Владимирович - доцент, кафедра общей и клинической фармакологии, Медицинский институт. SPIN-код: 8637-8963

Москва



И. И. Шкребнева
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Шкребнёва Ирина Ивановна - доцент, кафедра общей и клинической фармакологии, Медицинский институт. SPIN-код: 1105-5760

Москва



Д. А. Клюев
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Клюев Дмитрий Алексеевич - аспирант, кафедра общей и клинической фармакологии, Медицинский институт. SPIN-код: 8960-7798

Москва



Л. Н. Степанян
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Степанян Люсинэ Наириевна - аспирант, кафедра общей и клинической фармакологии, Медицинский институт

Москва



Список литературы

1. World Health Organization (2004) Atlas of Heart Disease and Stroke, Vol. 2015. WHO, Geneva.

2. WHO media centre. Cardiovascular diseases. http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 10 Jan 2016).

3. Okrainec K, Banerjee DK & Eisenberg MJ. Coronary artery disease in the developing world. American Heart Journal. 2004;148(1):7-15. DOI:10.1016/j.ahj.2003.11.027

4. Baroletti S & Dell’Orfano H. Medication Adherence in Cardiovascular Disease. Circulation. 2010;121(12):1455-1458.

5. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882-7.

6. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015;131:e29—322.

7. Clark AM, Hartling L, Vandermeer B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern. 2005;143:659-72.

8. Clark AM, Haykowsky M, Kryworuchko J, et al. A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2010;17:261-70.

9. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.

10. Turnbull F, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.

11. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682-92.

12. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.

13. Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532-40.

14. Briffa TG, Hobbs Ms, Tonkin A, et al. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2011;4:107-13.

15. World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO, 2003.

16. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. DOI:10.1111/j.1524-4733.2007.00213.x.

17. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2014:(11);1-730.

18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care.2005;43:521-30.

19. Lambert EV, Steyn K, Stender S, et al. Cross-cultural validation of the hill-bone compliance to high blood pressure therapy scale in a South African, primary healthcare setting. Ethn Dis. 2006;16:286-91.

20. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007;167:1798-803.

21. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.

22. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412-424.

23. Cutler DM, EverettW. Thinking outside the pillbox-medication adherence as a priority for health c.are reform. N Engl J Med. 2010;362:15531555.

24. Marcum ZA, Sevick MA, Handler SM. Medication nonadherence: a diagnosable and treatable medical condition. JAMA. 2013;309:2105-2106.

25. Ascertaining Barriers for Compliance: Policies for Safe, Effective and Cost-effective Use of Medicines in Europe. ABC Project newsletter [Internet]. 2009; Available from: http://abcproject.eu/img/ABC_newsletter_06_03_2009.pdf (29 July 2013).

26. Schmittdiel JA, Nichols GA, Dyer W, et al. Health care system-level factors associated with performance on Medicare STAR adherence metrics in a large, integrated delivery system. Med Care. 2015;53(4):332-7.

27. Chowdhuiy R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a metaanalysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-8.

28. Bowty AD, shrank WH, Lee JL, et al. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med. 2011;26:1479-91.

29. Laba T-L, Bleasel J, Brien J-A. Strategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged populations: a systematic review. International Journal of Cardiology. 2013;167(6):2430-2440.

30. Demonceau J, Ruppar T, Kristanto P, et al. Identification and assessment of aherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545-62.

31. Chen H-Y, Saczynski JS, Lapane KL, Kiefe CI, & Goldberg RJ. Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review. Heart & Lung: The Journal of Acute and Critical Care. 2015;44(4):299-308. DOI: 10.1016/j.hrtlng.2015.02.004

32. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028-1036.

33. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-1847.

34. Newby LK, LaPointe NMA, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203-212.

35. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.

36. Zullig LL, Ramos K & Bosworth H.B. Improving Medication Adherence in Coronary Heart Disease. Current Cardiology Reports. 2017;19(11). DOI:10.1007/s11886-017-0918-y

37. Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. European Journal of Clinical Pharmacology. 2011;67(4):407-414.

38. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. European Heart Journal. 2013;34(38):2940-2948. DOI: 10.1093/eurheartj/eht295

39. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.

40. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-576

41. Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662-1666

42. Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459-466

43. Rosenbaum L. Beyond belief — how people feel about taking medications for heart disease. N Engl J Med. 2015;372:183-7.

44. Santo K, Kirkendall S, Laba T-L, et al. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Preventive Cardiology 2016;23(10):1065-1076. DOI: 10.1177/2047487316638501

45. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345-56.

46. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn’t working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol. 2002;54:212-20.

47. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150:1377-8.

48. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-10.

49. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.

50. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418-425.

51. Lukina YV, Kutishenko NP, Martsevich SY. Treatment adherence: modern view on a well known issue. Cardiovascular Therapy and Prevention. 2017;16(1):91-95. DOI: 10.15829/1728-8800-2017-1-91-95

52. Spilker B. Methods of assessing and improving compliance in clinical trials. In: Cramer JA, Spilker B, eds. Patient compliance in medical practice and clinical trials. New York: Raven Press. 1991:37-56.

53. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-77. [Erratum, Ann Intern Med 2002;136:175.].

54. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004-6.

55. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures. Annals of Pharmacotherapy. 2006;40 (7-8),1280—1288. DOI:10.1345/aph.1h018.

56. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641.

57. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking. London: NCCSDO. 2005;40-6.

58. Nunes V, Neilson J, O’Flynn N, et al. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London: NICE 2009.

59. Čulig (Culig), Josip & Leppée, Marcel. From Morisky to Hill-Bone; self-reports scales for measuring adherence to medication. Collegium antropologicum. 2014;38:55-62.

60. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.

61. Wang Y, Lee J, Tang WE, Toh MP, Ko Y. Validity and reliability of a self-reported measure of medication adherence in patients with Type 2 diabetes mellitus in Singapore. Diabet Med. 2012;29:338-44.

62. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348-54.

63. Risser J, Jacobson TA, Kripalani S. Development and Psychometric Evaluation of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) in Low-Literacy Patients With Chronic Disease. Journal of Nursing Measurement. 2007;15(3):203-219. DOI: 10.1891/106137407783095757

64. Nguyen T-M-U, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring a systematic review. British Journal of Clinical Pharmacology. 2014;77(3),:427-445. DOI: 10.1111/bcp.12194

65. Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.

66. Willey C, Redding C, Stafford J, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22: 858-71.

67. Jonsdottir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30:169-75.

68. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17:17-32.

69. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32: 749-54.

70. Schroeder K, Fahey T, Hay AD, Montgomery A, Peters TJ. Adherence to antihypertensive medication assessed by self-report was associated with electronic monitoring compliance. J Clin Epidemiol. 2006;59:650-1.

71. Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008; 31:2037-43.

72. Schuz B, Wurm S, Ziegelmann JP, et al. Changes in functional health, changes in medication beliefs, and medication adherence. Health Psychol. 2011;30:31-9.

73. Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59-66.

74. Wang Y, Kong MC, Ko Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin. Thromb Haemost. 2012;108:1-7.

75. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the hill-bone compliance to high blood pressure therapy scale. Summer. 2000;15:90-6.

76. Fodor GJ, Kotrec M, Bacskai K, Dorner T, Lietava J, Sonkodi S, Rieder A, Turton P. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens 2005; 23: 1261—6.

77. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846—57.

78. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999; 37: 113—24.

79. Hahn SR, Park J, Skinner EP, Yu-Isenberg KS,Weaver MB, Crawford B, Flowers PW. Development of the ASK-20 adherence barrier survey. Curr Med Res Opin 2008; 24: 2127—38.

80. Matza LS, Yu-Isenberg KS, Coyne KS, Park J,Wakefield J, Skinner EP,Wolever RQ. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin 2008; 24: 3197—206.

81. Matza LS, Park J, Coyne KS, Skinner EP, Malley KG, Wolever RQ. Derivation and validation of the ASK-12 adherence barrier survey. Ann Pharmacother 2009; 43: 1621—30.

82. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health 2009; 12: 118—23.

83. Unni EJ, Farris KB. Development of a new scale to measure self-reported medication nonadherence. Res Social Adm Pharm. 2015 MayJun;11(3):e133-43. doi: 10.1016/j.sapharm.2009.06.005. Epub 2009 Oct 9..

84. Fernandez S, Chaplin W, Schoenthaler AM, Ogedegbe G. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med 2008; 31: 453—62.

85. Ogedegbe G,Mancuso CA, Allegrante JP, Charlson ME. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. J Clin Epidemiol 2003; 56: 520—9.

86. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004; 38: 1363—8.

87. van de Steeg N, Sielk M, Pentzek M, Bakx C, Altiner A. Drug-adherence questionnaires not valid for patients taking blood-pressure-lowering drugs in a primary health care setting. J Eval Clin Pract 2009; 15: 468—72.

88. Toll BA,McKee SA,Martin DJ, Jatlow P, O’Malley SS. Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit. Nicotine Tob Res 2007; 9: 597—605.

89. Hill-Briggs F, Gary TL, Bone LR, Hill MN, Levine DM, Brancati FL. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol 2005; 24: 349—57.

90. Vik SA, Maxwell CJ, Hogan DB, Patten SB, Johnson JA, RomonkoSlack L. Assessing medication adherence among older persons in community settings. Can J Clin Pharmacol 2005; 12: 152—64.

91. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A,Weaver C, Bennett S, Investigators NN-P, Coordinators. Self-reported adherence versus pill count in Parkinson’s disease: the NET-PD experience. Mov Disord 2007; 22: 822—7.

92. Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 2007; 69: 158—64.

93. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, DunbarJacob J. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43: 1203—7.

94. Gatti ME, Jacobson KL, Gazmararian JA, Schmotzer B, Kripalani S. Relationships between beliefs about medications and adherence. Am J Health Sys Pharm 2009; 66: 657—64.

95. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42: 241—7.

96. Haynes RB, McDonald H, GargAX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database SystRev. 2002;(2):CD000011.

97. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:I16-I18.

98. Cramer JA. Optimizing long-term patient compliance. Neurology 1995;45:Suppl 1:S25-S28.

99. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care 1997;8(4):43-54.

100. Connor J, Rafter N and Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935—939.

101. Fuller, R. H., Perel, P., Navarro-Ruan, T., Nieuwlaat, R., Haynes, R. B., & Huffman, M. D. (2018). Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart, 104(15), 1238—1243. doi:10.1136/heartjnl-2017-312571.

102. Jiang X, Sit JW and Wong TK. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: Evidence from Chengdu, China. J Clin Nurs 2007; 16: 1886—1897.

103. Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: A randomized clinical trial. JAMA Intern Med 2014; 174: 186—193.

104. Ma Y, Ockene IS, Rosal MC, et al. Randomized trial of a pharmacistdelivered intervention for improving lipid-lowering medication adherence among patients with coronary heart disease. Cholesterol 2010; 2010: 383281. DOI: 10.1155/2010/383281.

105. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: Results from the FOCUS project. J Am Coll Cardiol 2014; 64: 2071—2082.

106. Khonsari S, Subramanian P, Chinna K, et al. Effect of a reminder system using an automated short message service on medication adherence following acute coronary syndrome. Eur J Cardiovasc Nurs 2015; 14: 170—179.

107. Rinfret S, Rodes-Cabau J, Bagur R, et al. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation. Heart 2013; 99: 562—569.

108. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011; 365: 2088—2097.

109. Bond C. The MEDMAN study: A randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007; 24: 189—200.

110. Gould KA. A Randomized Controlled Trial of a Discharge Nursing Intervention to Promote Self-Regulation of Care for Early Discharge Interventional Cardiology Patients. Dimens Crit Care Nurs. 2011 MarApr;30(2):117-25. doi: 10.1097/DCC.0b013e3182052324.

111. Park LG, Howie-Esquivel J, Chung ML, et al. A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial. Patient Educ Couns 2014; 94: 261—268.

112. Xavier D, Gupta R, Kamath D, et al. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:244—53.

113. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918.


Для цитирования:


Фитилёв С.Б., Возжаев А.В., Шкребнева И.И., Клюев Д.А., Степанян Л.Н. Приверженность фармакотерапии сердечно-сосудистых заболеваний: современное состояние вопроса. Качественная клиническая практика. 2019;(4):66-80.

For citation:


Fitilev S.B., Vozzhaev A.V., Shkrebniova I.I., Kliuev D.A., Stepanyan L.N. Medication adherence in patients with cardiovascular disease: current view of the problem. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2019;(4):66-80. (In Russ.)

Просмотров: 268


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)